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OBJECTIVE
Weassessed dysglycemia and a T1DDiagnostic Index60 (Index60)‡1.00 (on the basis
of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic
end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Pre-
vention Study participants.
RESEARCH DESIGN AND METHODS
Two cohorts were analyzed: 1) baseline normoglycemic oral glucose tolerance tests
(OGTTs) with an incident dysglycemic OGTT and 2) baseline Index60 <1.00 OGTTs
with an incident Index60 ‡1.00 OGTT. Incident dysglycemic OGTTs were divided into
those with (DYS/IND+) and without (DYS/IND2) concomitant Index60 ‡1.00. Inci-
dent Index60 ‡1.00 OGTTs were divided into those with (IND/DYS+) and without
(IND/DYS2) concomitant dysglycemia.
RESULTS
The cumulative incidence for type 1 diabetes was greater after IND/DYS2 than after
DYS/IND2 (P < 0.01).Within the normoglycemic cohort, the cumulative incidence of
type 1 diabeteswas higher after DYS/IND+ than after DYS/IND2 (P< 0.001),whereas
within the Index60 <1.00 cohort, the cumulative incidence after IND/DYS+ and after
IND/DYS2 did not differ signiﬁcantly. Among nonprogressors, type 1 diabetes risk
at the last OGTT was greater for IND/DYS2 than for DYS/IND2 (P < 0.001). Hazard
ratios (HRs) ofDYS/IND2with age and 30- to 0-min C-peptidewere positive (P< 0.001
for both), whereas HRs of type 1 diabetes with these variables were inverse
(P < 0.001 for both). In contrast, HRs of IND/DYS2 and type 1 diabetes with age and
30- to 0-min C-peptide were consistent (all inverse [P < 0.01 for all]).
CONCLUSIONS
The ﬁndings suggest that incident dysglycemia without Index60 ‡1.00 is a suboptimal
prediagnostic end point for type 1 diabetes. Measures that include both glucose and
C-peptide levels, suchas Index60‡1.00, appearbetter suitedasprediagnostic endpoints.
The diagnosis of type 1 diabetes frequently occurs after the development of multiple
pancreatic autoantibodies and a gradual loss of b-cell function (1) occurring over a
period of several years (2–6). Thus, clinical trials (7–9) have determined whether
treatments during this period might delay or even prevent the development of the
disease. One of the challenges in conducting such trials is the length of time before
type 1 diabetes is diagnosed, even in high-risk populations (e.g., autoantibody-positive
individuals), which can result in costly trials of long duration. To reduce the length of
these trials, interest exists in using prediagnostic end points rather than the occurrence
of type 1 diabetes itself.
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The objective of this analysis was to
assess dysglycemia as a prediagnostic
end point in high-risk relatives of patients
with type 1 diabetes (two or more auto-
antibodies) and to compare the perfor-
mance between dysglycemia and a
T1D Diagnostic Index60 (Index60)
threshold$1.00. Dysglycemia is a known
predictor of type 1 diabetes (10) and has
been considered for use as a prediagnos-
tic end point. Index60 was developed
from a proportional hazards model and
combines the log fasting C-peptide level
with the 60-min glucose and 60-min
C-peptide levels fromoral glucose tolerance
tests (OGTTs). One analysis suggested that
an Index60 threshold$2.00 has value as a
diagnostic end point for type 1 diabetes
(11). Of note, the analysis also suggested
the possibility that a lower Index60
threshold could serve as a prediagnostic
end point. The comparison of these two
potential prediagnostic end points is of
particular interest because dysglycemia
is a marker for glucose alone, whereas
an Index60 threshold is a marker for glu-
cose and C-peptide combined.
RESEARCH DESIGN AND METHODS
Participants
Thedataused for theanalyseswerederived
from participants in the Type 1 Diabetes
TrialNet Pathway to Prevention (PTP) study
who had two or more autoantibodies at
screening. All participants were between
the ages of 1 and 45 years and were rel-
atives of patients with type 1 diabetes.
Individuals with diabetic-range baseline
OGTT resultswere excluded from the anal-
ysis. The PTP was approved by the institu-
tional review boards of all participating
sites (participating institutions can be
found in the Supplementary Data), and
written informed consent and assent,
as appropriate, were obtained from all
study participants.
Procedure
The PTP has been previously described
(12). Brieﬂy, after autoantibody screening,
participants positive for type 1 diabetes–
associated autoantibodies are followed
with 2-h OGTT surveillance at either 6-
or 12-month intervals according to their
risk for type 1 diabetes. All participants
analyzed for this report were followed
at 6-month intervals because thepresence
of two ormore autoantibodies is one of the
criteria for such follow-up. Autoantibodies
against GAD, IA2, and insulin are initially
measured at screening, and if one of these
autoantibodies is positive, islet cell cytoplas-
mic autoantibodies and zinc transporter
8 autoantibodies are then measured. All
autoantibodies have been measured from
the inception of the PTP except for zinc
transporter 8. For the 2-hOGTTs, C-peptide
and glucosemeasurements are obtained at
0, 30, 60, 90, and 120 min after the inges-
tion of 1.75 g/kg of carbohydrate (maxi-
mum 75 g). A diagnosis of type 1 diabetes
is made if an OGTT in the diabetic range
(fasting glucose $126 mg/dL, 2-h
glucose$200 mg/dL) is conﬁrmed by an-
other OGTT. If the second OGTT is not in
the diabetic range, participants continue to
be followed at 6-month intervals. A diagno-
sis could also be made on clinical grounds
(e.g., symptomatic with marked hypergly-
cemia). The glucose oxidase method was
used to measure plasma glucose. C-peptide
was measured by the Tosoh assay. Methods




dysglycemia and Index60 values $1.00. A
dysglycemic OGTT is a fasting glucose
value of 110–125 mg/dL; a 30-, 60-, and/
or 90-min glucose value $200 mg/dL;
and/or a 2-h glucose value of 140–
199 mg/dL. Index60 is calculated as
0.36953 (log fastingC-peptide [ng/mL]) +
0.0165 3 60-min glucose (mg/dL) –
0.36443 60-min C-peptide (ng/mL) (11).
Supplementary Fig. 1 is a ﬂow diagram
for the analytic design of the study. The
cohort selected for studying dysglycemia
as a prediagnostic end point had glucose
values in the normal glucose range at the
baseline OGTT (normoglycemia cohort),
whereas the cohort selected for study-
ing Index60 $1.00 as an end point had
Index60 values ,1.00 at the base-
line OGTT (Index60 ,1.00 cohort). The
normoglycemia cohort was followed
for the occurrence of the ﬁrst (inci-
dent) dysglycemic OGTT, whereas the
Index60 ,1.00 cohort was followed for
the occurrence of the ﬁrst (incident)
Index60 $1.00 OGTT. After the occur-
rence of the incident OGTT (incident
dysglycemia or incident Index60 $1.00),
each cohort was followed for the devel-
opment of type 1 diabetes. Among partic-
ipants with an incident dysglycemic
OGTT, those who also had concomi-
tant Index60 $1.00 at that time were
compared with those who did not.
Participants who did not progress to
type 1 diabetes were also compared for
the Diabetes Prevention Trial Risk Score
(DPTRS) (14) at the lastOGTT. Similar com-
parisons were made for those with an in-
cident Index60$1.00OGTT according to
whether concomitant dysglycemia was
present at that OGTT.
The DPTRS was developed to predict
the occurrence of type 1 diabetes in
autoantibody-positive relatives of patients
with type 1 diabetes. It was derived from a
proportional hazards model that includes
log fasting C-peptide, log BMI, age, and
the C-peptide sum and glucose sum
from30, 60, 90, and 120min. Themethod
for converting theDPTRS to risk estimates
has been previously described (14). The
conversion used for the current studywas
based on the overall survival curve for a
Type 1 Diabetes TrialNet population with
two or more autoantibodies at baseline.
By nature of the study design, some par-
ticipantsmet criteria for inclusion in both the
normoglycemia and the Index60,1.00 co-
horts. Those individuals were excluded
fromcomparisonsbetween incident dysgly-
cemiawithout concomitant Index60$1.00
(DYS/IND2) and incident Index60 $1.00
without concomitant dysglycemia (IND/
DYS2).
Log-rank tests were used to compare
cumulative incidence curves andwere ad-
justed for age by using a competing risk
regression model. Comparison of the dis-
tributionof age betweengroupswas done
by using the nonparametric Wilcoxon
ranksumtest.Hazardratios(HRs)werede-
rived fromproportional hazards regression
to examine associations of end points with
baseline variables. The t andx2 testswere
used to compare groups. Time-dependent
analyses for the area under the receiver
operating characteristic curve (AUCROC)
were based on the method of Uno et al.
(15). SAS 9.4 software was used for sta-
tistical analyses. P values are two-sided.
RESULTS
The following nomenclature is used
for the description of the ﬁndings. For the
normoglycemia cohort (n = 1,054, mean6
SD age 14.6 6 11.1 years, BMI z score
0.396 1.0) (Supplementary Table 1):
DYS/IND2 = incident dysglycemic OGTT
with concomitant Index60 value,1.00
DYS/IND+ = incident dysglycemic OGTT
with concomitant Index60 value$1.00
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For the Index60,1.00 cohort (n = 1,124,
age 16.26 11.8 years, BMI z score 0.436
1.0):
IND/DYS2 = incident Index60 $1.00
OGTT without concomitant dysglycemia
IND/DYS+ = incident Index60$1.00OGTT
with concomitant dysglycemia
Note that in the above nomenclature,
the incident dysglycemic OGTT always
starts with DYS, whereas the incident
Index60 $1.00 always starts with IND.
Risk of Type 1 Diabetes After Incident
Dysglycemic or Incident Index60 ‡1.00
OGTT
Figure 1A compares the cumulative inci-
dence for type 1 diabetes after the ﬁrst
dysglycemic OGTT between DYS/IND2
and DYS/IND+. The cumulative incidence
for type 1 diabetes after DYS/IND+ was
signiﬁcantly higher (P , 0.001) than the
cumulative incidence after DYS/IND2.
Figure 1B compares the cumulative in-
cidence for type 1 diabetes after the ﬁrst
Index60$1.00OGTTbetween IND/DYS2
and IND/DYS+. The cumulative incidence
of type 1 diabetes after IND/DYS+ was
somewhat higher than the cumulative in-
cidence for IND/DYS2 but not signiﬁ-
cantly (P = 0.30).
The cumulative incidence of type 1 di-
abetes after IND/DYS2 was signiﬁcantly
higher than that after DYS/IND2 (3-year
risk 0.34 [n = 65] vs. 0.20 [n = 100]; P ,
0.01). The IND/DYS2 OGTTs identiﬁed a
much younger population than that iden-
tiﬁed byDYS/IND2OGTTs (mean age 13.9
6 11.1 vs. 19.96 12.9 years; P = 0.002).
After adjustment for age, the difference
in cumulative incidence was smaller but
remained signiﬁcant (P = 0.029).
In summary, the cumulative incidence
of type 1 diabetes was similar between
IND/DYS2 and IND/DYS+, but the cumu-
lative incidence of type 1 diabetes was
greater for DYS/IND+ than for DYS/IND2.
Moreover, the cumulative incidence of
type 1 diabetes was greater for IND/DYS2
than for DYS/IND2.
Risk of Type 1 Diabetes at Last OGTT
(Among Participants Not Diagnosed)
After Having Incident Dysglycemia
or Incident Index60 ‡1.00
Table 1 shows DPTRS values at the last
visit among those who did not prog-
ress to type 1 diabetes (nonprogressors)
according to whether a prior incident
dysglycemic OGTT or a prior incident
Index60 $1.00 OGTT had occurred.
DPTRS values at the last OGTTwere higher
(P , 0.001) for the nonprogressors who
previously had DYS/IND+ than for nonpro-
gressors who previously had DYS/IND2
(5-year risk estimates from last OGTT
0.73 and 0.37, respectively). In contrast,
DPTRS values at the last visit did not dif-
fer signiﬁcantly (P = 0.42) between the
nonprogressors who previously had IND/
DYS+ and the nonprogressors who previ-
ouslyhad IND/DYS2 (5-year risk estimates
from last OGTT 0.75 and 0.65, respectively).
In a comparison between nonprogressors
who previously had DYS/IND2 and non-
progressorswhopreviouslyhad IND/DYS2,
DPTRS values at the last visit were signif-
icantly higher (P , 0.001) in the latter
(5-year risk estimates from last OGTT
0.49 [n = 36] vs. 0.30 [n = 80]).
In summary, the risk for type 1 diabetes
among nonprogressors at the last OGTT
was similar between those who previ-
ously had IND/DYS2 and those who had
IND/DYS+, but the risk was greater for
those who previously had DYS/IND+
than for thosewhohadDYS/IND2.More-
over, the risk for type 1 diabetes at the
last visit was greater for IND/DYS2 than
for DYS/IND2.
Prediction Accuracy
An analysis was performed of the AUCROC
integrated over the time of follow-up after
the incident Index60 $1.00 and incident
dysglycemic OGTTs. Among participants
with an incident Index60 $1.00 OGTT,
the presence or absence of concomitant
dysglycemia contributed little to the pre-
dictionof type1 diabetesbeyond the con-
tribution of incident Index60 $1.00; the
integrated AUCROC of dysglycemia for
predicting type 1 diabetes was only 0.48,
which is close to the null value for no con-
tribution (0.50). The AUCROC P values
at each year of follow-up were 0.97 at
1 year, 0.05 at 2 years, 0.66 at 3 years,
0.51 at 4 years, and 0.20 at 5 years. In
contrast, among those with an incident
dysglycemic OGTT, the presence or ab-
senceof concomitant Index60$1.00 con-
tributed appreciably to the prediction of
Figure 1—A: Comparisons of cumulative incidence curves for type 1 diabetes (T1D) after incident dysglycemia according to concomitant Index60$1.00.
The cumulative incidence for T1D is substantially higher if there is concomitant Index60$1.00. B: Comparisons of cumulative incidence curves for T1D
after incident Index60 $1.00 according to concomitant dysglycemia. The difference between the cumulative incidence curves is much smaller after
incident Index60 $1.00 than after incident dysglycemia. *Both indicates incident dysglycemia with concomitant Index60 $1.00 (DYS/IND+). **Both
indicates incident Index60$1.00 with concomitant dysglycemia (IND/DYS+).
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type 1 diabetes beyond the contribution
of incident dysglycemia; the integrated
AUCROC of Index60$1.00 for predicting
type 1 diabetes was 0.68. The AUCROC
P values at each year of follow-up were
,0.001at1year,,0.001 at 2 years,,0.01
at 3 years, ,0.05 at 4 years, and 0.13 at
5 years.
In summary, when incident Index60
$1.00 occurred, the presence or absence
of concomitant dysglycemia did not add
to the prediction of type 1 diabetes. On
the other hand, when incident dysglyce-
mia occurred, the presence or absence of
Index60$1.00 added to the prediction of
type 1 diabetes.
ComparisonsofDYS/IND2 and IND/DYS2
With Type 1 Diabetes for Associations
With Baseline Variables
We examined the consistency of HRs
between DYS/IND2 and type 1 diabetes
(as end points) for associations with
baseline variables in the same cohort
(normoglycemic OGTTs at baseline). The
data showed a discordance between DYS/
IND2 and type 1 diabetes for HRs with
several baseline variables (Fig. 2 and Sup-
plementary Table 2). Speciﬁcally, the
HRs of DYS/IND2 with age, log fasting
C-peptide, C-peptide sum, and 30- to
0-min C-peptide difference were in
opposite directions to the HRs of type 1 di-
abeteswith thosevariables (positive forDYS/
IND2 and inverse for type 1 diabetes).
Moreover, all the HRs were statistically
signiﬁcant (P , 0.001) in the opposite
directions. The HRs of DYS/IND2 and
type 1 diabetes with autoantibody number
(any combination of the four antibodies
tested) were also in opposite directions, in-
verse forDYS/IND2 andpositive for type 1
diabetes; the HRwas signiﬁcant for type 1
diabetes (P , 0.001) but not for DYS/
IND2 (P = 0.16). The HRs of DYS/IND2
and type1 diabeteswere only concordant
for the glucose sum (P, 0.001 for both).
In contrast, among the cohort with
Index60 ,1.00 at baseline, the HRs of
IND/DYS2 with the aforementioned
baseline variables were similar to the
HRs of type 1 diabeteswith those variables
(Fig. 3 and Supplementary Table 3), with
all being in the same direction (inverse)
and signiﬁcant. The HRs of IND/DYS2 and
type 1 diabetes were also concordant for
the glucose sum (both positive and signif-
icant). The directionality of the HRs of
IND/DYS2 and of type 1 diabetes with
autoantibody number was also the same
(positive for both); the HR was signiﬁcant
for type 1 diabetes (P, 0.001) but not for
IND/DYS2 (P = 0.14).
Diabetes autoantibody proﬁles were
evaluated between DYS/IND2 and
IND/DYS2 (Supplementary Table 4). No
signiﬁcant differences in the frequen-
cies of autoantibodies for GAD and insulin
or for islet cell cytoplasmic autoanti-
bodies were found between the cohorts.
A difference of borderline signiﬁcance
(P = 0.045) was found in the frequency
of IA2 autoantibodies between the
cohorts.
In summary, associations with age and
C-peptide variables were more consis-
tent between IND/DYS2 and type 1 di-
abetes than between DYS/IND2 and
type 1 diabetes. DYS/IND2 and type 1
diabetes differed in the directionality of
their associations with age and C-peptide
variables.
CONCLUSIONS
The ﬁndings suggest that incident dysgly-
cemia in the absence of Index60 $1.00
(i.e., DYS/IND2) has shortcomings as a
prediagnostic end point for type 1 diabe-
tes. On the basis of their level of risk, a
number of individuals who have incident
dysglycemia without Index60 $1.00
might not ultimately progress to type 1
diabetes. The uncertain progression to
type 1 diabetes is further supported by ev-
idence that the associations of DYS/IND2
with several baseline variables (including
age, C-peptide measures, and autoanti-
body number) differ in directionality from
the associations of type 1 diabetes with
those same baseline variables.
As a measure that includes both glucose
and C-peptide information, Index60$1.00
has promise as a prediagnostic end point.
In direct statistical comparisons between
participants with DYS/IND2 and those
with IND/DYS2, the cumulative incidence
Figure 2—HRs with 95% CIs of DYS/IND2 and of type 1 diabetes for associations with baseline
variables. The HRs of DYS/IND2 are discordant from the HRs of type 1 diabetes. Speciﬁcally, for age
and each C-peptide variable, the HR and 95% CI (all positive) of DYS/IND2 is on the opposite side of
the null value (i.e., 1.0) from the HR and 95% CI (all inverse) of type 1 diabetes. The HR of DYS/IND2
and autoantibody number is inverse and on the opposite side of the null value from the HR of type 1
diabetes and autoantibody number; however, the 95% CI for the HR of type 1 diabetes overlaps
the null value. The two panels are shown with different scales to encompass all the variables. DM,
diabetes.
Table 1—DPTRS values and 5-year risk estimates at last visit among individuals with
incident dysglycemia or incident Index60 ‡1.00 OGTTs who did not progress to
type 1 diabetes
Incident dysglycemia Incident Index60 $1.00
Index60,1.00 (n = 92) Index60$1.00 (n = 40) No dysglycemia (n = 50) Dysglycemia (n = 38)
5.936 1.56 (0.37) 7.64 6 1.32 (0.73)† 7.27 6 1.44 (0.65) 7.52 6 1.33 (0.75)
Data are mean6 SD (5-year estimate from the last visit derived from DPTRS). Higher DPTRS values
signify a greater risk for type 1 diabetes. †P , 0.001 for comparison of incident dysglycemia and
Index60$1.00 with incident dysglycemia and Index60,1.00.
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for type 1 diabetes was appreciably
higher after IND/DYS2.Moreover, among
those who did not progress to type 1 di-
abetes, DPTRS values at the last visit
were higher for those who had IND/DYS2.
In addition, IND/DYS2 outperformed
DYS/IND2 with regard to prediction ac-
curacy and consistency with type 1 diabe-
tes for associations with the baseline
variables.
The lower risk of type 1 diabetes for
DYS/IND2 and its opposite directionality
of associations with baseline variables to
that of type 1 diabetes have implications
beyond identifying optimal prediagnostic
end points. These ﬁndings suggest that
even among individuals with two or more
autoantibodies who develop dysglycemia,
outcomes besides type 1 diabetes are not
uncommon. Some individuals could re-
vert to an ongoing normoglycemic state,
some could develop type 2 diabetes or
other forms of diabetes, or some could
have either intermittent dysglycemia or
continuing dysglycemia without progres-
sion to type 1 diabetes. Thus, those who
developdysglycemia, even in thepresence
of autoantibodies, could be heteroge-
neous with varying outcomes. IND/DYS2
appears to be more centered on the
pathway to a type 1 diabetes outcome
than DYS/IND2. The much older age at
the time of the DYS/IND2 OGTTs sup-
ports this view.
The number of individuals who devel-
oped incident dysglycemia was greater
than the numberwho developed incident
Index60 $1.00. This consideration is im-
portant because the number who reach
an end point could affect the length and
cost of a prevention trial. However, if
DYS/IND2 were excluded because of its
questionable performance as a prediag-
nostic end point, the number of individu-
als with incident dysglycemia would
be less than the number with incident
Index60$1.00.
Few studies have speciﬁcally examined
potential prediagnostic end points for
type 1 diabetes. In one study, changes in
HbA1c and area under the curve C-peptide
over a 2-year period suggested the possi-
bility that metabolic markers can be used
as intermediate end points for type 1
diabetes (16).
A limitation of the current studywas the
lack of conﬁrmation of the prediagnostic
end points because the PTP study was not
designed to assess these end points. Pro-
tocols that use prediagnostic end points
would likely require conﬁrmation. Another
limitation is the possibility that slow pro-
gression to type 1 diabetes was not cap-
tured during the follow-up period.
The PTP represents a much older pop-
ulation than at-risk cohorts followed from
birth or a young age (17) for the develop-
ment of autoantibodies and ultimately
type 1 diabetes. Children from those co-
horts who develop multiple autoanti-
bodies are at a very high lifetime risk for
type 1 diabetes. The uncertainty of the
ultimate development of type 1 diabetes
for those with multiple autoantibodies
and DYS/IND2 in the PTP highlights the
importance of age as a modiﬁer of risk for
type 1 diabetes. Thus, the possible hetero-
geneityofoutcomes inolder, autoantibody-
positive populations with dysglycemia
deserves further exploration. A better un-
derstanding of the diverse outcomes that
could occur would help to reﬁne the de-
sign of type 1 diabetes prevention trials.
A major difference between dysglyce-
mia and Index60 is that the latter combines
both glucose and C-peptide information,
which could be the main explanation for the
superior performance of Index60 $1.00.
Although the choice of a prediagnostic
end point partially depends on the nature
of theprevention trial, consideration should
be given for developing prediagnostic end
points for type 1 diabetes that combine
glucose and C-peptide information, such
as Index60$1.00.
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Figure 3—HRs with 95% CIs of IND/DYS2 and of type 1 diabetes for associations with baseline
variables. The HRs of IND/DYS2 are concordant with the HRs of type 1 diabetes. Speciﬁcally, for age
and each C-peptide variable, the HR and 95% CI of IND/DYS2 is on the same side of the null value
(i.e., 1.0) as theHRand95%CI (all inverse) of type 1diabetes. TheHRof IND/DYS2 and autoantibody
number is also positive and on the same side of the null value as the HR of type 1 diabetes and
autoantibody number; however, the 95%CI for theHRof type1diabetesoverlaps the null value. The
two panels are shown with different scales to encompass all the variables. DM, diabetes.
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